Mepivacaína Dermogen (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. By preventing sodium influx, the drug stops the initiation and propagation of nerve impulses, resulting in a reversible loss of sensation in the area where it is administered.

The appropriate dose of Mepivacaína Dermogen is determined by the prescribing clinician based on the type of procedure, patient weight, age, and clinical condition. Dosage guidelines are provided in the product label, and the prescriber tailors the amount to achieve effective anesthesia while minimizing toxicity.

Safety data for mepivacaine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both mepivacaine and lidocaine are amide‑type local anesthetics, but mepivacaine typically has a slightly faster onset and a moderate duration of action, whereas lidocaine may have a shorter duration. Choice between them depends on the clinical setting, desired block length, and patient‑specific factors such as allergy history.

Mepivacaína Dermogen should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight and extreme temperatures. Do not freeze the product, and ensure the container is sealed when not in use to maintain sterility.

The product is administered by a qualified healthcare professional via infiltration or perineural injection. The solution is injected directly into the target tissue or around a nerve bundle using aseptic technique. Proper aspiration before injection helps avoid intravascular administration.

Serious adverse events include allergic reactions such as anaphylaxis, cardiac arrhythmias, central nervous system toxicity (e.g., seizures), methemoglobinemia, and severe hypotension. Immediate medical attention is required if any of these symptoms develop during or after administration.

Patients with a known hypersensitivity to mepivacaine or other amide‑type local anesthetics should avoid the product. It is also contraindicated in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or those who have received a recent intravascular injection of a similar anesthetic.